1208361-39-0Relevant articles and documents
ERK1/2 protein kinase inhibitor and application thereof
-
Paragraph 0127-0129, (2021/03/31)
The present invention provides a compound represented by formula (I), or isomers and pharmaceutically acceptable salts thereof, and uses of the compound, isomer and pharmaceutically acceptable salts in preparation of ERK1/2 mediated disease drugs.
6-bromo-3H-pyrrolo(2,1-f)(1,2,4)triazine-4-ketone preparation method
-
, (2019/02/06)
The invention belongs to the technical field of medicine and specifically relates to a 6-bromo-3H-pyrrolo(2,1-f)(1,2,4)triazine-4-ketone preparation method. The method comprises the following steps: reacting 2,5-dimethoxy tetrahydrofuran with tert-butylcarbazate to obtain compound IV; then reacting with trichloro-acetic chloride to obtain compound V; bromizing to obtain compound Vi; performing esterification reaction to obtain compound VII; finally, cyclizing to obtain 6-bromo-3H-pyrrolo(2,1-f)(1,2,4)triazine-4-ketone. Compared with the prior art, the preparation method disclosed by the invention greatly improves the yield and the purity of 6-bromo-3H-pyrrolo(2,1-f)(1,2,4)triazine-4-ketone, reduces production cost and has good application value.
TGF BETA RECEPTOR ANTAGONISTS
-
Page/Page column 151; 152, (2017/03/08)
The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβ R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.